LON:FARNFaron Pharmaceuticals Oy Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Faron Pharmaceuticals Oy Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 357.50 +7.50 (+2.14 %) (As of 06/1/2020 04:00 PM ET) Add Compare Share Today's Range 347Now: GBX 357.50▼ 36250-Day Range 337.50MA: GBX 367.86▼ 442.5052-Week Range 79Now: GBX 357.50▼ 595Volume35,045 shsAverage Volume14,501 shsMarket Capitalization£167.28 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsInsider TradesHeadlines Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute organ traumas, vascular damage, and cancer immunotherapy. The company's lead product candidate is Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS). It also develops Clevegen, a pre-clinical immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Faron Pharmaceuticals Oy. Previous Next 3.2 Community Rank Outperform VotesFaron Pharmaceuticals Oy has received 317 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFaron Pharmaceuticals Oy has received 184 “underperform” votes. (Add your “underperform” vote.)Community SentimentFaron Pharmaceuticals Oy has received 63.27% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Faron Pharmaceuticals Oy and other stocks. Vote “Outperform” if you believe FARN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FARN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFaron Pharmaceuticals Oy does not currently pay a dividend.Dividend GrowthFaron Pharmaceuticals Oy does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Faron Pharmaceuticals Oy insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Faron Pharmaceuticals Oy is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Faron Pharmaceuticals Oy is -3.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFaron Pharmaceuticals Oy has a P/B Ratio of 14.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.64 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:FARN Previous Symbol CUSIPN/A CIKN/A Webwww.faron.com Phone+358-2-4695151Debt Debt-to-Equity Ratio175.28 Current Ratio1.52 Quick Ratio1.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 25.10 per share Price / Book14.24Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees18 Outstanding Shares46,790,700Market Cap£167.28 million Next Earnings DateN/A OptionableNot Optionable LSE:FARN Rates by TradingView Receive FARN News and Ratings via Email Sign-up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter. Faron Pharmaceuticals Oy (LON:FARN) Frequently Asked Questions How has Faron Pharmaceuticals Oy's stock been impacted by COVID-19 (Coronavirus)? Faron Pharmaceuticals Oy's stock was trading at GBX 297.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FARN stock has increased by 20.2% and is now trading at GBX 357.50. View which stocks have been most impacted by Coronavirus. Has Faron Pharmaceuticals Oy been receiving favorable news coverage? News stories about FARN stock have trended very negative this week, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Faron Pharmaceuticals Oy earned a daily sentiment score of -3.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutFaron Pharmaceuticals Oy. Who are some of Faron Pharmaceuticals Oy's key competitors? Some companies that are related to Faron Pharmaceuticals Oy include Oxford BioMedica (OXB), Bellus Health (BLU), CEL-SCI (CVM), Cel-Sci (CVM), Paradigm Biopharmaceuticals (PAR), SIGA Technologies (SIGA), Biotest (BIO), Neptune Wellness Solutions (NEPT), Silence Therapeutics (SLN), TELIX Pharmaceutical (TLX), Starpharma (SPL), Medicenna Therapeutics (MDNA), ProMetic Life Sciences (PLI), IMV (IMV) and Emblem (EMC). View all competitors. What other stocks do shareholders of Faron Pharmaceuticals Oy own? Based on aggregate information from My MarketBeat watchlists, some companies that other Faron Pharmaceuticals Oy investors own include Horizon Discovery Group (HZD), Celgene (CELG), Acura Pharmaceuticals (ACUR), Alphabet (GOOG), Northwest Pipe (NWPX), TriQuint Semiconductor (TQNT), Allstate (ALL), Allergy Therapeutics (AGY), Argentex Group (AGFX) and Alpha FX Group (AFX). Who are Faron Pharmaceuticals Oy's key executives? Faron Pharmaceuticals Oy's management team includes the following people: Mr. Yrjö Erik Kristian Wichmann, CFO & Exec. Director (Age 61)Dr. Juho Markku Jalkanen, Chief Devel. Officer (Age 41)Dr. Markku Tapani Jalkanen Ph.D., Founder, CEO & Exec. Director (Age 64)Dr. Mikael Maksimow Ph.D., VP of Operations (Age 43)Dr. Matti Karvonen, Chief Medical Officer & VP of Drug Devel. What is Faron Pharmaceuticals Oy's stock symbol? Faron Pharmaceuticals Oy trades on the London Stock Exchange (LON) under the ticker symbol "FARN." How do I buy shares of Faron Pharmaceuticals Oy? Shares of FARN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Faron Pharmaceuticals Oy's stock price today? One share of FARN stock can currently be purchased for approximately GBX 357.50. How big of a company is Faron Pharmaceuticals Oy? Faron Pharmaceuticals Oy has a market capitalization of £167.28 million. Faron Pharmaceuticals Oy employs 18 workers across the globe. What is Faron Pharmaceuticals Oy's official website? The official website for Faron Pharmaceuticals Oy is www.faron.com. How can I contact Faron Pharmaceuticals Oy? Faron Pharmaceuticals Oy's mailing address is Intelligate, Joukahaisenkatu 6, TURKU, 20520, Finland. The company can be reached via phone at +358-2-4695151. This page was last updated on 6/1/2020 by MarketBeat.com Staff
